title: Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis.
abstract: A multiplexed MNPs-Abs based fluorescence spectroscopic system in analysis of serum biomarkers; CA-125, β2-M and ApoA1 for the early detection of ovarian cancer was first time proposed. The lowest detection limits measured in multiplexed setup were 0.26 U/mL, 0.55 ng/mL and 7.7 ng/mL respectively for CA-125, β2-M and ApoA1. A comparative real sample analysis of healthy normal (Control), benign and ovarian cancer patients with SPR has also been done to validate the process. Moreover CA-125 detection only confirms 50-60% of early stage disease. This multiplexed system achieved sensitivity and specificity up to 94% and 98% respectively to distinguish early stage ovarian cancer patients from healthy individuals.
authors.affiliation: Department of Life Sciences Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 84105, Israel.
authors.forename: Manoj K
authors.initials: MK
authors.lastname: Pal
authors.affiliation: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi 110062, India; Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Buraydah Private Colleges, Al-Qassim 31717, Kingdom of Saudi Arabia.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Rashid
authors.affiliation: Seemant Institute of Technology, Pithoragarh 262501, India. Electronic address: bishtmanisha83@gmail.com.
authors.forename: Manisha
authors.initials: M
authors.lastname: Bisht
mesh_terms: D000328:Adult; D055910:Antibodies, Immobilized; D016632:Apolipoprotein A-I / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D016022:Case-Control Studies; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D057230:Limit of Detection; D058185:Magnetite Nanoparticles; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D058726:Nanoconjugates; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D011379:Prognosis; D013050:Spectrometry, Fluorescence / Q000379:methods*; D020349:Surface Plasmon Resonance / Q000379:methods*; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: C505693:APOA1 protein, human; D055910:Antibodies, Immobilized; D016632:Apolipoprotein A-I; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D058185:Magnetite Nanoparticles; D008565:Membrane Proteins; D058726:Nanoconjugates; D001613:beta 2-Microglobulin
keywords: Antibodies; Biosensor; Functionalized MNPs; Multiplexed; Ovarian cancer